Department of Defense Amyotrophic Lateral Sclerosis Research Program
FY17 ALSRP Program Announcements and General Application Instructions for the following award mechanisms posted on the Grants.gov website.
As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, Research, Development and Acquisition (DHA RDA) Directorate manages the Defense Health Program (DHP) Research, Development, Test and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP).
Therapeutic Development Award –Pre-application due June 9, Full Application August 31
Independent investigators at all academic levels
Pre-application is required; full application submission is by invitation only.
Supports post-discovery, preclinical development of therapeutics for ALS
Preliminary data, including identify and purity of an identified bioactive compound(s), are required
Types of efforts that will be supported include:
o Validation of lead pharmacological agents up to IND submission
o Optimization of potency and pharmacology, studies of formulation, stability and production methods based on Good Manufacturing Practices
Collaboration with industry is encouraged
Clinical trials are not allowed
Does not support screening or development of screens or models
Maximum funding of $1,000,000 for direct costs (plus indirect costs)
Maximum period of performance is 2 years
Therapeutic Idea Award – Pre-application due June 9, Full application due August 31
Independent investigators at all academic levels
Pre-application is required; application submission is by invitation only.
Supports hypothesis-driven drug discovery efforts focused on ALS therapeutics
Preliminary data are not required
Types of efforts that will be supported include:
o Novel exploitation of pathways known to be relevant to ALS for the purpose of improving treatment and/or advancing a novel treatment modality
o Development, validation and use of novel of high-throughput screens and model systems based on novel targets or innovative drug systems
o Development of methods for measuring engagement of mechanistic targets by drug candidates
Innovation in technologies and techniques is an important criteria
Maximum funding of $500,000 for direct costs (plus indirect costs)
Maximum period of performance is 2 years Characterization of mechanisms for the purpose of identifying new targets is outside of the scope of this announcement
A pre-application is required and must be submitted through the CDMRP electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.
Full applications must be submitted through the federal government's single-entry portal, Grants.gov. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from Grants.gov. The application package containing the required forms for each award mechanism can be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.
For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the ALSRP or other CDMRP administered programs, please visit the CDMRP website (http://cdmrp.army.mil).
